A Phase 3, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-Term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus.

Next Previous
Trial Profile

A Phase 3, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-Term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2011

At a glance

  • Drugs Ipragliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Oct 2011 Actual end date (July 2011) added as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top